AbbVie Buys Into Obesity With Gubra Deal, While Novo Partners With Gensaic

AbbVie is the latest big pharma to buy into the obesity space, licensing an amylin analog from Gubra for $350m up front, while Novo will pursue cardiometabolic targets with Gensaic’s AI-based platform.